Abstract: Modified polyimines and derivatives thereof suitable as implantable medical devices and coatings therefore are provided. Specifically, implantable medical devices and/or coatings comprise amphiphilic polymers derived from modified polyimines. The medical devices and coatings of the present invention can also be used for in situ nitric oxide release/controlled release drug delivery and are useful for treating or preventing medical conditions such as restenosis, aneurysms and vulnerable plaque.

Abstract: Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed wherein the solubility parameters of polymers and drugs are closely matched to control elute rate profiles. The present application also discloses providing vascular stents with controlled release coatings and related methods for making these coatings.

Abstract: The present invention provides a system for treating a vascular condition, including a catheter, a stent coupled to the catheter, a drug-polymer coating on the stent including a polymeric blend of a phenoxy polymer and a styrenic block copolymer, and a bioactive drug dispersed within the drug-polymer coating.

Abstract: This invention provides modified biopolymers comprising biopolymers attached to at least one non-proteinaceous catalyst capable of dismutating superoxide in the biological system or precursor ligand thereof. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.

Abstract: Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed. The present application also discloses providing vascular stents with controlled release coatings and related methods for making these coatings. Additional embodiments of the present invention include stents coated with the disclosed copolymer(s) and peptide drugs. Methods for treating or inhibiting post-stent implantation restenosis in patients are also provided.

Abstract: This invention provides modified biopolymers comprising biopolymers attached to at least one non-proteinaceous catalyst capable of dismutating superoxide in the biological system or precursor ligand thereof. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.

Abstract: The present invention provides a system for treating a vascular condition, which includes a catheter; a stent coupled to the catheter, the stent including a stent framework; a phenoxy primer coating operably disposed on the stent framework; and a drug-polymer coating disposed on the phenoxy primer coating. The present invention also provides a drug-coated stent and a method of manufacturing a drug-coated stent.

Abstract: The present invention provides a system for treating a vascular condition, including a catheter, a stent coupled to the catheter, a drug-polymer coating on the stent including a grafted styrenic block copolymer, and at least one bioactive drug dispersed within the drug-polymer coating.

Abstract: Implantable medical devices having a nanoparticle coating applied thereon. The nanoparticle coating comprises nanopulverized antiproliferative compounds. More specifically, the nanoparticulate antiproliferative compounds comprise particles less than 500 nm in size. The nanoparticle size of the compounds improves compounds' solubility. In addition to improving the solubility of otherwise insoluable antiproliferative compounds, the nanoparticle size minimizes the preparation and formulation required to prepare a dose of the antiproliferative compounds.

Abstract: Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed wherein the solubility parameters of polymers and drugs are closely matched to control elute rate profiles. The present application also discloses providing vascular stents with controlled release coatings and related methods for making these coatings.

Abstract: The gradient coated stent 150 of the present invention provides a coated stent having a continuous coating 130 disposed on the stent elements. The continuous coating 130 includes a first coating component and a second coating component. The concentration of the first coating component varies continuously over at least part of the thickness of the continuous coating 130. The concentration of the second coating component can also vary over at least part of the thickness of the continuous coating 130. In one embodiment, the concentration of the first coating component decreases in the direction from the stent element towards the outer edge of the continuous coating 130 and the concentration of the second coating component increases in the direction from the stent element towards the outer edge of the continuous coating 130.

Abstract: Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of drugs from medical devices in vivo are disclosed wherein the porosity of the polymer coatings is varied to control elute rate profiles. Also disclosed are vascular stents and stent grafts with controlled release coatings and related methods for making these coatings.

Abstract: The present invention provides a system for treating a vascular condition, including a catheter; a stent with a stent framework that is coupled to the catheter; a polymeric coating of a blended matrix of a polysulfone and a styrenic block copolymer that is disposed on the stent framework, and a therapeutic agent in contact with the matrix. A drug-polymer coated stent, a method of manufacturing a drug-polymer coated stent, and method for treating a vascular condition are also disclosed.

Abstract: The present invention provides a system for treating a vascular condition, including a catheter, a stent with a stent framework operably coupled to the catheter, and a drug-polymer coating on the stent framework including at least one plasticizer dispersed within the drug-polymer coating.

Abstract: The present invention provides a system for treating a vascular condition, which includes a catheter; a stent coupled to the catheter, the stent including a stent framework; a phenoxy primer coating operably disposed on the stent framework; and a drug-polymer coating disposed on the phenoxy primer coating. The present invention also provides a drug-coated stent and a method of manufacturing a drug-coated stent.

Abstract: The present invention provides a system for treating a vascular condition, comprising a catheter; a stent coupled to the catheter, the stent including a stent framework; an epoxy primer coating disposed on the stent framework; and a drug-polymer coating disposed on the epoxy primer coating. The present invention also provides an epoxy-coated stent, a drug-coated stent with an epoxy primer coating, and a method of manufacturing the coated stents.

Abstract: The present invention provides a system for treating a vascular condition, including a catheter, a stent coupled to the catheter, a drug-polymer coating on the stent including a grafted styrenic block copolymer, and at least one bioactive drug dispersed within the drug-polymer coating.

Abstract: The present invention provides a system for treating a vascular condition, including a catheter, a stent coupled to the catheter, a drug-polymer coating on the stent including a polymeric blend of a phenoxy polymer and a styrenic block copolymer, and a bioactive drug dispersed within the drug-polymer coating.

Abstract: This invention provides modified biopolymers comprising biopolymers attached to at least one non-proteinaceous catalyst capable of dismutating superoxide in the biological system or precursor ligand thereof. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.

Abstract: The present invention relates to hyaluronic acid polymers modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.